In prostate cancer, plasma DNA analysis is being increasingly used to identify molecular aberrations but it is not yet a validated test in clinical practice such as and testing of plasma epidermal growth factor receptor (EGFR) mutations, which represents one of current molecular tools in oncology approved by the Food and Drug Administration (FDA) for the treatment selection of EGFR tyrosine kinase inhibitors in mutant lung cancer patients [77]. This evidence concerns the gene EGFR and prostate cancer.